95 related articles for article (PubMed ID: 17506942)
1. Effect of telmisartan on expression of protein kinase C-alpha in kidneys of diabetic mice.
Yao LJ; Wang JQ; Zhao H; Liu JS; Deng AG
Acta Pharmacol Sin; 2007 Jun; 28(6):829-38. PubMed ID: 17506942
[TBL] [Abstract][Full Text] [Related]
2. [Protein kinase C-betaI, betaII in mouse diabetic nephropathy kidney and its relation to nephroprotective actions of the angiotensin receptor blocker telmisartan].
Yao LJ; Wang JQ; Deng AG; Liu JS
Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(28):1991-5. PubMed ID: 17923043
[TBL] [Abstract][Full Text] [Related]
3. Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1-7) mas receptor expression associated with its PPAR-γ agonist action.
Lakshmanan AP; Watanabe K; Thandavarayan RA; Sari FR; Harima M; Giridharan VV; Soetikno V; Kodama M; Aizawa Y
Free Radic Res; 2011 May; 45(5):575-84. PubMed ID: 21381899
[TBL] [Abstract][Full Text] [Related]
4. Effects of blocking the renin-angiotensin system on expression and translocation of protein kinase C isoforms in the kidney of diabetic rats.
Zhang L; Ma J; Gu Y; Lin S
Nephron Exp Nephrol; 2006; 104(3):e103-11. PubMed ID: 16837815
[TBL] [Abstract][Full Text] [Related]
5. Effect of Micardis on the expression of renal medulla aquaporin-2 in diabetic mice.
Yao L; Wang J; Deng A; Liu J; Zhao H
J Huazhong Univ Sci Technolog Med Sci; 2008 Jun; 28(3):272-5. PubMed ID: 18563321
[TBL] [Abstract][Full Text] [Related]
6. Effect of telmisartan on VEGF-induced and VEGF-independent angiogenic responsiveness of coronary endothelial cells in normal and streptozotocin (STZ)-induced diabetic rats.
Chaudagar KK; Mehta AA
Clin Exp Hypertens; 2014; 36(8):557-66. PubMed ID: 24490705
[TBL] [Abstract][Full Text] [Related]
7. Effect of telmisartan on the expression of cardiac adiponectin and its receptor 1 in type 2 diabetic rats.
Guo Z; Zheng C; Qin Z; Wei P
J Pharm Pharmacol; 2011 Jan; 63(1):87-94. PubMed ID: 21155820
[TBL] [Abstract][Full Text] [Related]
8. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats.
Kobayashi N; Ohno T; Yoshida K; Fukushima H; Mamada Y; Nomura M; Hirata H; Machida Y; Shinoda M; Suzuki N; Matsuoka H
Am J Hypertens; 2008 May; 21(5):576-81. PubMed ID: 18437150
[TBL] [Abstract][Full Text] [Related]
9. Does telmisartan prevent hepatic fibrosis in rats with alloxan-induced diabetes?
Halici Z; Bilen H; Albayrak F; Uyanik A; Cetinkaya R; Suleyman H; Keles ON; Unal B
Eur J Pharmacol; 2009 Jul; 614(1-3):146-52. PubMed ID: 19406119
[TBL] [Abstract][Full Text] [Related]
10. Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model.
Meier M; Park JK; Overheu D; Kirsch T; Lindschau C; Gueler F; Leitges M; Menne J; Haller H
Diabetes; 2007 Feb; 56(2):346-54. PubMed ID: 17259378
[TBL] [Abstract][Full Text] [Related]
11. Meprin-alpha in chronic diabetic nephropathy: interaction with the renin-angiotensin axis.
Mathew R; Futterweit S; Valderrama E; Tarectecan AA; Bylander JE; Bond JS; Trachtman H
Am J Physiol Renal Physiol; 2005 Oct; 289(4):F911-21. PubMed ID: 15942051
[TBL] [Abstract][Full Text] [Related]
12. Combination of telmisartan with sildenafil ameliorate progression of diabetic nephropathy in streptozotocin-induced diabetic model.
El-Mahdy NA; El-Sayad ME; El-Kadem AH
Biomed Pharmacother; 2016 Jul; 81():136-144. PubMed ID: 27261587
[TBL] [Abstract][Full Text] [Related]
13. Telmisartan, an angiotensin II type 1 receptor blocker, prevents the development of diabetes in male Spontaneously Diabetic Torii rats.
Hasegawa G; Fukui M; Hosoda H; Asano M; Harusato I; Tanaka M; Shiraishi E; Senmaru T; Sakabe K; Yamasaki M; Kitawaki J; Fujinami A; Ohta M; Obayashi H; Nakamura N
Eur J Pharmacol; 2009 Mar; 605(1-3):164-9. PubMed ID: 19171132
[TBL] [Abstract][Full Text] [Related]
14. Telmisartan prevents the progression of renal injury in daunorubicin rats with the alteration of angiotensin II and endothelin-1 receptor expression associated with its PPAR-γ agonist actions.
Arozal W; Watanabe K; Veeraveedu PT; Ma M; Thandavarayan RA; Sukumaran V; Suzuki K; Kodama M; Aizawa Y
Toxicology; 2011 Jan; 279(1-3):91-9. PubMed ID: 20888384
[TBL] [Abstract][Full Text] [Related]
15. Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice.
Iwanami J; Mogi M; Tsukuda K; Min LJ; Sakata A; Jing F; Iwai M; Horiuchi M
J Hypertens; 2010 Aug; 28(8):1730-7. PubMed ID: 20498620
[TBL] [Abstract][Full Text] [Related]
16. Telmisartan, a dual ARB/partial PPAR-γ agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetes.
Goyal SN; Bharti S; Bhatia J; Nag TC; Ray R; Arya DS
Diabetes Obes Metab; 2011 Jun; 13(6):533-41. PubMed ID: 21320264
[TBL] [Abstract][Full Text] [Related]
17. Telmisartan activates endogenous peroxisome proliferator-activated receptor-δ and may have anti-fibrotic effects in human mesangial cells.
Mikami D; Kimura H; Kamiyama K; Torii K; Kasuno K; Takahashi N; Yoshida H; Iwano M
Hypertens Res; 2014 May; 37(5):422-31. PubMed ID: 24352213
[TBL] [Abstract][Full Text] [Related]
18. Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy.
Vieitez P; Gómez O; Uceda ER; Vera ME; Molina-Holgado E
J Renin Angiotensin Aldosterone Syst; 2008 Jun; 9(2):96-102. PubMed ID: 18584585
[TBL] [Abstract][Full Text] [Related]
19. Immunolocalization of protein kinase C isoenzymes alpha, beta I, beta II, delta, and epsilon in mouse kidney.
Redling S; Pfaff IL; Leitges M; Vallon V
Am J Physiol Renal Physiol; 2004 Aug; 287(2):F289-98. PubMed ID: 15039141
[TBL] [Abstract][Full Text] [Related]
20. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.
Liao J; Kobayashi M; Kanamuru Y; Nakamura S; Makita Y; Funabiki K; Horikoshi S; Tomino Y
J Nephrol; 2003; 16(6):841-9. PubMed ID: 14736011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
